Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)

Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling is commonly dysregulated in acute lymphoblastic leukemia (ALL). The TACL2014-001 phase I trial of the mTOR inhibitor temsirolimus in combination with cyclophosphamide and etoposide was performed in children and adole...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasian, Sarah K., Silverman, Lewis B., Whitlock, James A., Sposto, Richard, Loftus, Joseph P., Schafer, Eric S., Schultz, Kirk R., Hutchinson, Raymond J., Gaynon, Paul S., Orgel, Etan, Bateman, Caroline M., Cooper, Todd M., Laetsch, Theodore W., Sulis, Maria Luisa, Chi, Yueh-Yun, Malvar, Jemily, Wayne, Alan S., Rheingold, Susan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Acute Lymphoblastic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521241/
https://www.ncbi.nlm.nih.gov/pubmed/35112552
http://dx.doi.org/10.3324/haematol.2021.279520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521241/
https://www.ncbi.nlm.nih.gov/pubmed/35112552
http://dx.doi.org/10.3324/haematol.2021.279520

Ejemplares similares